• Corpus ID: 26430434

Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.

@article{vanHennik1987ComparativePO,
  title={Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.},
  author={M B van Hennik and Wim J.F. van der Vijgh and Ina Klein and F. Elferink and Jan Baptist Vermorken and Benjamin Winograd and Herbert Michael Pinedo},
  journal={Cancer research},
  year={1987},
  volume={47 23},
  pages={
          6297-301
        }
}
Pharmacokinetics of cisplatin, spiroplatin, ethylenediaminemalonatoplatinum(II) (JM-40), and carboplatin was studied in BALB/c x DBA/2 F1 mice receiving 10% lethal doses of 15.5, 6.8, 100, and 165 mg/kg, respectively. Blood samples were collected for up to 5 days after a single i.v. bolus injection. Total platinum in plasma and non-protein-bound free platinum in plasma ultrafiltrate were determined by flameless atomic absorption spectrometry. Parent JM-40 and carboplatin were determined by high… 

Tables from this paper

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
TLDR
Although JM-40 and carboplatin are structurally closely related, pharmocokinetics and toxicity ofJM-40 were more similar to cis-platin than tocarboplatin.
Clinical Pharmacokinetics of Carboplatin
TLDR
In contrast to results from animal studies, the modulation of carboplatin-induced myelo-suppression by diethyldithiocarbamate (DDTC) was not clinically successful, and the low bioavailability and the gastrointestinal side effects observed did not warrant further studies with oral administration.
A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)
TLDR
Toxicity is predictable with linear pharmacokinetics, as was predicted by preclinical studies, and a dose of 120 mg m−2 every 21 days is recommended for Phase II evaluation although there is evidence that chemo-naive patients and those of good performance status may tolerate a higher dose.
Phase I study of spiroplatin.
Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews
TLDR
The platinum concentrations detected in the brain could potentially contribute to the neurological side effects of cisplatin, such as nausea and emesis.
Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice.
TLDR
The extent of distribution of platinum into tissues (lung, liver, muscle, kidney) was markedly influenced by conjugation, with the influence being greatest for unmodified cisplatin and least for the A5B7-CMdextran conjugate.
Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
TLDR
Dox is rapidly formed from Leu-Dox, and seems causative in the observed myelotoxicity, which means that the MTD could not be predicted from the preclinical pharmacokinetics in mice.
Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells
TLDR
The results suggest that phenoxodiol has interesting properties that make combination therapy with cisplatin or carboplatin appealing.
Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
  • D. NewellA. Pearson M. Stevens
  • Medicine, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
GFR-based carboplatin dosing in children should be feasible and will be evaluated prospectively, and two further equations were developed that use the 51Cr-EDTA half-life (t1/2) to calculate the GFR and these may reduce errors resulting from inaccurate measurement of the volume of distribution for 51Cr -EDTA.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
TLDR
Ethylenediamine platinum(II) malonate (JM-40) was less emetic in the ferret and less nephrotoxic in the dog, while its antitumor activity approached that of cisplatin, and limited evaluation of JM-40 in phase II studies is warranted.
Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.
TLDR
The binding of platinum to both plasma and proteins and rbcs in vitro (using patients' own blood) was slow, biphasic, and irreversible.
Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin.
TLDR
It is concluded that mouse serum protein-bound platinum does not contribute significantly to cisplatin antitumor activity and toxicity in mice.
Kinetics of cis‐dichlorodiammineplatinum
TLDR
The cancer chemotherapeutic cis‐dichlorodiammineplatinum (cis‐DDP) was administered to 8 patients and the non‐protein‐bound platinum was found to be rapidly and biphasically cleared from the plasma with half‐life values of 8 to 10 min and 40 to 45 min.
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
TLDR
If the starting dose in Phase 1 clinical trials had been selected by calculating one-third of the toxic dose low (in mg/sq m) in the most sensitive large animal species, 5 of the 30 drugs would have produced significant toxicity in the first patient.
Renal toxicity studies of protein-bound platinum(cis).
Clinical Experience with 1, 1-Diaminomethylcyclohexane (Sulphato) Platinum (II) (TNO-6)
TLDR
Although nephrotoxicity is generally considered as the major dose limiting toxicity, methods to overcome this toxicity have created the possibility to administer multiple courses of the drug, with prolonged treatment other toxicities may become dose-limiting.
Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.
TLDR
Over 178 patients have been treated for a variety of malignant conditions and approximately half of these patients received the platinum compound alone and the other half received it in combination with four other chemotherapeutic agents.
Potential roles for preclinical pharmacology in phase I clinical trials.
TLDR
Retrospective analyses indicate that 20%-50% savings in the total number of dose escalations are possible, and potential strategies for controlling the rate of dose escalation based upon pharmacokinetic determinations in mouse and man are explored.
...
...